James K Karras

US Patent:

6727064, Apr 27, 2004

Filed:

Jan 11, 2001

Appl. No.:

09/758881

Inventors:

James G. Karras - San Marcos CA

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C12Q 168

US Classification:

435 6, 435325, 435375, 536 231, 536 245

Abstract:

Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

US Patent:

7098192, Aug 29, 2006

Filed:

Feb 6, 2004

Appl. No.:

10/773678

Inventors:

James G. Karras - San Marcos CA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 48/00
C07H 21/04
C07H 21/02
C12Q 1/68

US Classification:

514 44, 536 231, 536 243, 536 245, 435 6

Abstract:

Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

US Patent:

7176303, Feb 13, 2007

Filed:

Nov 6, 2003

Appl. No.:

10/704263

Inventors:

Susan M. Freier - San Diego CA, US
James Karras - Carlsbad CA, US

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/04

US Classification:

536 245, 435 5, 435 6, 435 912, 536 231, 536 243, 536 2431, 536 2433

Abstract:

Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.

US Patent:

7307069, Dec 11, 2007

Filed:

Mar 15, 2006

Appl. No.:

11/376033

Inventors:

James G. Karras - San Marcos CA, US

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/04
C07H 21/02
A61K 48/00
C12Q 1/68

US Classification:

514 44, 435 6, 435325, 435375, 536 231, 536 243, 536 245

Abstract:

Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and cancers, associated with overexpression or constitutive activation of STAT3 or insufficient apoptosis are also provided.

US Patent:

7507810, Mar 24, 2009

Filed:

Oct 11, 2006

Appl. No.:

11/548650

Inventors:

James G. Karras - San Marcos CA, US
Susan Gregory - San Diego CA, US
Susan M. Freier - San Diego CA, US
William A. Gaarde - Carlsbad CA, US
Mausumee Guha - Carlsbad CA, US

Assignee:

ISIS Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/04
C07H 21/02
A61K 48/00

US Classification:

536 245, 536 231, 536 243, 514 44

Abstract:

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and/or pulmonary inflammation.

US Patent:

7585968, Sep 8, 2009

Filed:

Mar 27, 2006

Appl. No.:

11/390894

Inventors:

James G. Karras - San Marcos CA, US
Kenneth W. Dobie - Del Mar CA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/02
C07H 21/04

US Classification:

536 245, 536 231, 536 243, 536 2433

Abstract:

Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and/or pulmonary inflammation.

US Patent:

7709628, May 4, 2010

Filed:

Nov 3, 2006

Appl. No.:

11/556565

Inventors:

Susan M. Freier - San Diego CA, US
James G. Karras - San Marcos CA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

C07H 21/04

US Classification:

536 245, 536 2431, 536 241, 435 6, 435325, 435375, 514 44

Abstract:

Compounds, compositions and methods are provided for modulating the expression of STAT5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT5. Methods of using these compounds for modulation of STAT5 expression and for diagnosis and treatment of diseases and conditions associated with expression of STAT5 are provided.

US Patent:

8153603, Apr 10, 2012

Filed:

Feb 24, 2006

Appl. No.:

11/816705

Inventors:

James G. Karras - San Marcos CA, US
Susan Gregory - San Diego CA, US
Jeffrey R. Crosby - Carlsbad CA, US
Mausumee Guha - La Costa CA, US
David Tung - Superior CO, US
Susan M. Freier - San Diego CA, US

Assignee:

Isis Pharmaceuticals, Inc. - Carlsbad CA

International Classification:

A61K 48/00
C07H 21/04

US Classification:

514 44, 536 231, 536 245

Abstract:

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and/or pulmonary inflammation.